Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.72 |
| ▸ | BRD4 | O60885 | 9/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | NT5C2 | P49902 | 2/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536913 | 1.00 | BRAF (0.72) | BRAFBRD4NPC1RAB9ACYP1A2 | |
| SCHEMBL22118772 | 0.85 | BRD4 (0.68) | BRAFBRD4NPC1RAB9ACYP1A2 | |
| SCHEMBL5437612 | 0.83 | BRD4 (0.62) | BRAFBRD4NPC1RAB9ACYP1A2 | |
| SCHEMBL17362837 | 0.83 | BRD4 (0.58) | BRAFBRD4NPC1RAB9ACYP1A2 | |
| SCHEMBL29799431 | 0.83 | BRD4 (0.58) | BRAFBRD4NPC1RAB9ACYP1A2 | |
| SCHEMBL8720615 | 0.83 | BRD4 (0.58) | BRAFBRD4NPC1RAB9ACYP1A2 | |
| SCHEMBL8718918 | 0.81 | BRD4 (0.57) | BRAFBRD4NPC1RAB9ACYP1A2 | |
| SCHEMBL28828155 | 0.81 | BRD4 (0.59) | BRAFBRD4NPC1RAB9ACYP1A2 | |
| SCHEMBL28669706 | 0.81 | NPC1 (0.63) | BRAFBRD4NPC1RAB9ACYP1A2 | |
| SCHEMBL11481134 | 0.80 | BRD4 (0.56) | BRAFBRD4NPC1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111430-A1 | CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4687992-A1 | LIPID-BASED NANOPARTICLE TARGETED AT ACTIVATED IMMUNE CELLS FOR THE EXPRESSION OF IMMUNE CELL INHIBITING MOLECULE AND USE THEREOF | OSE IMMUNOTHERAPEUTICS (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4687991-A1 | LIPID-BASED NANOPARTICLE TARGETED AT ACTIVATED IMMUNE CELLS FOR THE EXPRESSION OF IMMUNE CELL ENHANCING MOLECULE AND USE THEREOF | OSE IMMUNOTHERAPEUTICS (FR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025111452-A2 | CHEMICAL MODIFICATIONS IN PEgRNA and ngRNAs | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025080995-A1 | PHARMACEUTICAL AGENT-INTEGRIN LIGAND CONJUGATES FOR MUSCLE DELIVERY | ADARX PHARMACEUTICALS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250108007-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2025-04-03 | — | — | US | disclosed |
| WO-2025052180-A2 | LIPIDS AND LIPID NANOPARTICLES | Axelyf ehf. (IS) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025036992-A1 | RNA CONJUGATES | CureVac SE (DE) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025038960-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2024199282-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 苏州艾博生物科技有限公司 | 2024-10-03 | — | — | WO | disclosed |
| WO-2024109798-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 苏州艾博生物科技有限公司 | 2024-05-30 | — | — | WO | disclosed |
| WO-2024083171-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 苏州艾博生物科技有限公司 | 2024-04-25 | — | — | WO | disclosed |
| WO-2024083172-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 苏州艾博生物科技有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-116064598-B | Nucleic acid vaccine for coronavirus | 苏州艾博生物科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2024022263-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 苏州艾博生物科技有限公司 | 2024-02-01 | — | — | WO | disclosed |
| WO-2023116804-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 苏州艾博生物科技有限公司 | 2023-06-29 | — | — | WO | disclosed |
| CN-116064598-A | Nucleic acid vaccine for coronavirus | 苏州艾博生物科技有限公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2023067560-A1 | IONIZABLE CATIONIC COMPOUND | Seqirus Inc. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067561-A1 | IONIZABLE CATIONIC LIPID FOR MESSENGER RNA DELIVERY | Seqirus Inc. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022065413-A1 | NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF | 株式会社理研ジェネシス | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108007-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | CETP, NPC1, LCAT | BRAF 3131/4885BRD4 3013/4885NPC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.